There are currently 34 clinical trials in Oceanside, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Excell Research, Inc, Excell Research, Dermatology Specialists Inc. and North County Clinical Research. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
Recruiting
The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Neurocrine Clinical Site, Oceanside, California
Conditions: Schizophrenia
PD, PK, and Safety of ALTO-203 in Patients With MDD
Recruiting
The goal of this clinical trial is to determine the pharmacodynamic effects of ALTO-203 in patients with MDD in a randomized, placebo-controlled, single-dose crossover treatment period. Additionally, safety, tolerability, and PK will be assessed in a subsequent randomized placebo-controlled multi-dose parallel-group treatment period of 28 days. Participants will complete subjective response questionnaires and perform cognitive tasks during the single-dose period, in which participants will rece... Read More
Gender:
All
Ages:
Between 25 years and 64 years
Trial Updated:
06/19/2024
Locations: Site 4082, Oceanside, California
Conditions: Major Depressive Disorder, Anhedonia
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
Recruiting
The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/18/2024
Locations: Excell Research, Inc., Oceanside, California
Conditions: Major Depressive Disorder
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
Recruiting
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with moderate-to-severe anhedonia (ANH+) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Gender:
All
Ages:
Between 18 years and 74 years
Trial Updated:
06/18/2024
Locations: Excell Research Inc, Oceanside, California
Conditions: Depressive Disorder, Major, Anhedonia
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
Recruiting
The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor [SSRI] or serotonin and norepinephrine reuptake inhibitor [SNRI]) in all participants with major depressive disorder (MDD).
Gender:
All
Ages:
Between 18 years and 74 years
Trial Updated:
06/18/2024
Locations: Excell Research Inc, Oceanside, California
Conditions: Depressive Disorder, Major
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Recruiting
This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequate response to their current atypical antipsychotic treatment. The primary objective of the study is to assess the efficacy of adjunctive KarXT (a fixed dose combination of xanomeline and trospium chloride twice daily [BID]) versus placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positiv... Read More
Gender:
All
Ages:
Between 18 years and 59 years
Trial Updated:
06/17/2024
Locations: Clinical Trial Site, Oceanside, California
Conditions: Schizophrenia
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Recruiting
This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/14/2024
Locations: Alliance Clinical Research, Oceanside, California
Conditions: Crohn Disease
Study to Evaluate the Effects of Oral NMRA 335140 Versus Placebo in Participants With Major Depressive Disorder
Recruiting
This is a randomized, double blind, placebo controlled, multi-center study to evaluate the effects of NMRA 335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA 335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/13/2024
Locations: Neumora Investigator Site, Oceanside, California
Conditions: Major Depressive Disorder
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Recruiting
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), who provide informed consent, and who have no evidence of safety concerns that would preclude treatment with NMRA-335140 may be enrolled into this ext... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/13/2024
Locations: Neumora Investigator Site, Oceanside, California
Conditions: Major Depressive Disorder
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
Recruiting
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months,... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/12/2024
Locations: Vistagen Clinical Site, Oceanside, California
Conditions: Social Anxiety Disorder
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder
Recruiting
The purpose of this trial is to measure the efficacy, safety, and tolerability of darigabat (25 milligrams [mg] twice daily [BID]) compared with placebo in participants with panic disorder.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/11/2024
Locations: Oceanside, California, Oceanside, California
Conditions: Panic Disorder
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Recruiting
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and adolescents (a... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/05/2024
Locations: Excell Research, Inc /ID# 230899, Oceanside, California
Conditions: Migraine